Mecbotamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Cervical Cancer. According to Globaldata, it is involved in 5 clinical trials, of which 3 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Mecbotamab vedotins valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Mecbotamab vedotin is expected to reach an annual total of $45 mn by 2038 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Mecbotamab vedotin Overview
BA-3011 is under development for the treatment of solid tumors include non-squamous non-small cell lung cancer (NSCLC), oral cancer, castration-resistant prostate cancer (CRPC), bladder cancer, breast cancer, fallopian tube cancer and peritoneal cancer, colorectal cancer, oral cancer, cervical cancer, ovarian cancer, head and neck cancer, liver cancer, lung cancer, melanoma, stomach cancer, pancreatic cancer, soft tissue sarcoma, bone sarcoma, and endometrial cancer, chondrosarcoma, adenoid cystic carcinoma (ACC), renal cell carcinoma, leiomyosarcoma. The drug candidate acts by targeting AXL receptor tyrosine kinase. The drug candidate is developed based on conditionally active biologics (CAB) platforms.
It was under development for Ewing sarcoma, osteosarcoma, synovial sarcoma, liposarcoma and mesothelioma of the pleura.
BioAtla Overview
BioAtla is a biotech company that develops novel monoclonal antibody and cell-based therapeutics using proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms. The company’s pipeline products candidate includes BA3011 (mecbotamab vedotin) targets undifferentiated pleomorphic sarcoma, non-small cell lung cancer; BA3021 (ozuriftamab vedotin) for melanoma, squamous cell carcinoma of the head and neck; BA3182 treat adenocarcinomas; BA3361 for multiple tumor types; and BA3071 (Evalstotug) treat melanoma, non-small cell lung cancer (NSCLC) and carcinomas. BioAtla is headquartered in San Diego, California, the US.
The operating loss of the company was US$129.7 million in FY2023, compared to an operating loss of US$108.1 million in FY2022. The net loss of the company was US$123.5 million in FY2023, compared to a net loss of US$106.5 million in FY2022.
For a complete picture of Mecbotamab vedotins valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
